{"id":22820,"date":"2026-08-17T10:21:44","date_gmt":"2026-08-17T08:21:44","guid":{"rendered":"https:\/\/mic-site.labiux.com\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/"},"modified":"2026-08-17T10:21:44","modified_gmt":"2026-08-17T08:21:44","slug":"plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/","title":{"rendered":"Plau\u0161u v\u0113zis &#8211; bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m"},"content":{"rendered":"<div class=\"wp-block-labiux-legacy-html legacy-content\">\n<p>Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts apmaks\u0101tu skr\u012bningu cilv\u0113kiem ar augstu saslim\u0161anas risku, k\u0101 tas notiek cit\u0101s valst\u012bs.<\/p>\n<p>Latvij\u0101 ik gadu plau\u0161u v\u0113zi diagnostic\u0113 aptuveni 900 \u20131000 cilv\u0113kiem. 2023. gad\u0101 no bronhu un plau\u0161u v\u0113\u017ea nomira 949 cilv\u0113ki, un tas bija bie\u017e\u0101kais ar \u013caundab\u012bgajiem audz\u0113jiem saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Piecu gadu izdz\u012bvot\u012bba plau\u0161u v\u0113\u017ea pacientiem joproj\u0101m ir \u013coti zema \u2013 aptuveni 16%, turkl\u0101t liela da\u013ca slim\u012bbas gad\u012bjumu tiek diagnostic\u0113ti III vai IV stadij\u0101, kad \u0101rst\u0113\u0161anas iesp\u0113jas un prognoze ir b\u016btiski slikt\u0101kas, liecina Slim\u012bbu profilakses un kontroles centra dati.<\/p>\n<p><strong>Daudzi nezina, ka saslimt var ar\u012b nesm\u0113\u0137\u0113t\u0101ji<\/strong><\/p>\n<p>Plau\u0161u v\u0113zis ir \u013coti nopietna un smaga slim\u012bba &#8211; Eirop\u0101 tas ir tre\u0161ais bie\u017e\u0101kais n\u0101ves c\u0113lonis aiz infarkta un insulta, uzsver <strong>Alvils Krams<\/strong>, LU profesors, pneimonologs, Latvijas Tuberkulozes un plau\u0161u slim\u012bbu \u0101rstu asoci\u0101cijas vad\u012bt\u0101js. Lai gan sm\u0113\u0137\u0113\u0161ana ir galvenais plau\u0161u v\u0113\u017ea riska faktors, k\u0101 nor\u0101da A. Krams, ir mald\u012bgi dom\u0101t, ka ar plau\u0161u v\u0113zi saslimst tikai sm\u0113\u0137\u0113t\u0101ji.<\/p>\n<p>\u201cPaties\u012bb\u0101 plau\u0161u v\u0113zis var att\u012bst\u012bties ar\u012b nesm\u0113\u0137\u0113t\u0101jiem, un to var veicin\u0101t ar\u012b citi faktori k\u0101 azbests, radons, kas ir dab\u0101 sastopama radioakt\u012bva g\u0101ze, k\u0101 ar\u012b pas\u012bv\u0101 sm\u0113\u0137\u0113\u0161ana, iedzimt\u012bba, darba vide, vides faktori u.c. Diem\u017e\u0113l tikai aptuveni katrs ceturtais l\u012bdz piektais plau\u0161u v\u0113\u017ea gad\u012bjums tiek diagnostic\u0113ts agr\u012bni &#8211; stadij\u0101s, kad \u0101rst\u0113\u0161anas iesp\u0113jas un prognoze ir iev\u0113rojami lab\u0101kas,\u201d uzsver A. Krams.<\/p>\n<p>Par plau\u0161u v\u0113zi joproj\u0101m past\u0101v daudz mald\u012bgu priek\u0161statu. Uz\u0146\u0113muma \u201cSolid Data\u201d pavasar\u012b veikt\u0101 Latvijas iedz\u012bvot\u0101ju aptauja atkl\u0101j &#8211; lai gan pas\u012bv\u0101 sm\u0113\u0137\u0113\u0161ana ir b\u016btisks plau\u0161u v\u0113\u017ea riska faktors, vair\u0101k nek\u0101 ceturt\u0101 da\u013ca jeb 27% aptauj\u0101to Latvijas iedz\u012bvot\u0101ju piekr\u012bt apgalvojumam, ka pas\u012bv\u0101 sm\u0113\u0137\u0113\u0161ana b\u016btiski nepalielina plau\u0161u v\u0113\u017ea risku. V\u0113l 12% uz \u0161o jaut\u0101jumu atbild\u0113ju\u0161i \u201cnezinu\u201d. Tas noz\u012bm\u0113, ka gandr\u012bz \u010detri no desmit respondentiem vai nu nenov\u0113rt\u0113 pas\u012bv\u0101s sm\u0113\u0137\u0113\u0161anas saist\u012bbu ar plau\u0161u v\u0113\u017ea risku vai nav p\u0101rliecin\u0101ti par t\u0101s noz\u012bmi, kas nor\u0101da uz \u013coti v\u0101ju izpratni par plau\u0161u v\u0113\u017ea profilaksi.<\/p>\n<p><strong>Klepu bie\u017ei neuzskata par probl\u0113mu<\/strong><\/p>\n<p>Aptauja par\u0101da ar\u012b citu sabiedr\u012bb\u0101 izplat\u012btu mald\u012bgu priek\u0161statu &#8211; teju tre\u0161da\u013ca jeb 31% respondentu piekr\u012bt apgalvojumam, ka tad, ja cilv\u0113kam nav klepus vai elpo\u0161anas gr\u016bt\u012bbu, ar plau\u0161\u0101m viss ir k\u0101rt\u012bb\u0101. \u0160\u0101ds uzskats var b\u016bt \u012bpa\u0161i riskants, jo plau\u0161u v\u0113zis agr\u012bn\u0101s stadij\u0101s p\u0101rsvar\u0101 noris bez skaidri paman\u0101miem simptomiem vai ir ar nespecifisk\u0101m s\u016bdz\u012bb\u0101m, kuras cilv\u0113ks s\u0101kotn\u0113ji nesaista ar nopietnu slim\u012bbu. T\u0101p\u0113c svar\u012bgi ir veicin\u0101t izpratni par riska faktoriem, tostarp sm\u0113\u0137\u0113\u0161anas kait\u012bgumu, nepiecie\u0161am\u012bbu savlaic\u012bgi v\u0113rsties pie \u0101rsta, k\u0101 ar\u012b veikt m\u0113r\u0137\u0113tu agr\u012bnu diagnostiku cilv\u0113kiem ar paaugstin\u0101tu risku, uzsver onkologs \u0137\u012bmijterapeits <strong>Viktors Kozirovskis<\/strong>.<\/p>\n<p>Aptaujas dati nor\u0101da ar\u012b uz nepiln\u012bgu izpratni par att\u0113ldiagnostikas iesp\u0113j\u0101m: 41% respondentu piekr\u012bt apgalvojumam, ka kr\u016b\u0161ukurvja rentgenogramma ir pietiekami efekt\u012bva agr\u012bnai plau\u0161u v\u0113\u017ea atkl\u0101\u0161anai. Lai gan rentgenogr\u0101fija var b\u016bt viens no izmekl\u0113jumiem konkr\u0113tu s\u016bdz\u012bbu izv\u0113rt\u0113\u0161an\u0101, t\u0101 nav uzskat\u0101ma par pietiekamu metodi plau\u0161u v\u0113\u017ea atkl\u0101\u0161anai, jo 27% gad\u012bjumu var nepar\u0101d\u012bt agr\u012bnas izmai\u0146as.<\/p>\n<p><strong>Aicina diskut\u0113t par plau\u0161u v\u0113\u017ea skr\u012bninga ievie\u0161anu<\/strong><\/p>\n<p>Plau\u0161u v\u0113\u017ea skr\u012bning\u0101 jeb plau\u0161u vesel\u012bbas izv\u0113rt\u0113\u0161an\u0101 starptautiski k\u0101 efekt\u012bv\u0101ka metode tiek izmantota zemas devas datortomogr\u0101fija, kas \u013cauj detaliz\u0113t\u0101k izv\u0113rt\u0113t plau\u0161u audus un agr\u0101k paman\u012bt izmai\u0146as, uzsver radiolo\u0123e, RSU profesore, Latvijas Radiologu asoci\u0101cijas p\u0101rst\u0101ve <strong>Maija Radzi\u0146a<\/strong>.<\/p>\n<p>\u201cValsts organiz\u0113ts plau\u0161u v\u0113\u017ea skr\u012bnings ar datortomogr\u0101fijas metodi pacientiem bez simptomiem ir l\u0113t\u0101kais un efekt\u012bv\u0101kais veids, k\u0101 agr\u012bni atkl\u0101t plau\u0161u v\u0113zi un saslimu\u0161ajiem uzlabot \u0101rst\u0113\u0161anas rezult\u0101tus. Agr\u012bna \u0101rst\u0113\u0161anas uzs\u0101k\u0161ana b\u016btiski ietaupa valsts izmaksas. Valst\u012bs, kur\u0101s skr\u012bnings darbojas, agr\u012bni atkl\u0101tu gad\u012bjumu \u012bpatsvars var sasniegt 70%,\u201d nor\u0101da V. Kozirovskis.<\/p>\n<p>\u201cAr\u012b Latvij\u0101 ir pien\u0101cis laiks valsts politikas l\u012bmen\u012b s\u0101kt nopietni diskut\u0113t par plau\u0161u v\u0113\u017ea skr\u012bninga ievie\u0161anu. Kam\u0113r pie mums \u0161is jaut\u0101jums v\u0113l tiek apspriests, Igaunij\u0101 plau\u0161u v\u0113\u017ea skr\u012bnings uzs\u0101kts jau 2022. gad\u0101, bet Lietuv\u0101 \u2013 2024. gad\u0101. Starptautisk\u0101 pieredze liecina, ka agr\u012bnas radiolo\u0123isk\u0101s p\u0101rbaudes var b\u016btiski samazin\u0101t mirst\u012bbu no plau\u0161u v\u0113\u017ea un pal\u012bdz\u0113t slim\u012bbu atkl\u0101t agr\u012bn\u0101k, kad \u0101rst\u0113\u0161ana ir efekt\u012bv\u0101ka un izmaksas \u2013 maz\u0101kas nek\u0101 v\u0113l\u012bn\u0101s stadij\u0101s,\u201d uzsver Maija Radzi\u0146a.<\/p>\n<p>Vienlaikus ir b\u016btiski pan\u0101kt, lai cilv\u0113kiem, kuriem plau\u0161u v\u0113zis tiek atkl\u0101ts, b\u016btu pieejama m\u016bsdien\u012bga un efekt\u012bva \u0101rst\u0113\u0161ana. Latvija jaun\u0101ko medikamentu pieejam\u012bbas zi\u0146\u0101 joproj\u0101m b\u016btiski atpaliek no daudz\u0101m Eiropas valst\u012bm ierobe\u017eot\u0101 valsts finans\u0113juma d\u0113\u013c. M\u016bsdienu onkolo\u0123ij\u0101 arvien liel\u0101ka noz\u012bme ir personaliz\u0113tai terapijai, im\u016bnterapijai un cit\u0101m inovat\u012bv\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas daudzos gad\u012bjumos var iev\u0113rojami pagarin\u0101t pacientu dz\u012bvi un uzlabot t\u0101s kvalit\u0101ti, ta\u010du plau\u0161u v\u0113\u017ea pacientiem Latvij\u0101 \u0161\u012bs iesp\u0113jas nav pieejamas l\u012bdzv\u0113rt\u012bg\u0101 apjom\u0101, uzsver V. Kozirovskis. Savlaic\u012bga diagnostika un efekt\u012bvas \u0101rst\u0113\u0161anas pieejam\u012bba ir b\u016btisk\u0101kie priek\u0161noteikumi, lai mazin\u0101tu plau\u0161u v\u0113\u017ea izrais\u012bto mirst\u012bbu Latvij\u0101.<\/p>\n<p>Izmantotie avoti:<\/p>\n<p>Slim\u012bbu profilakses un kontroles centra Vesel\u012bbas statistikas datub\u0101ze \u2013 ONKO030, ONKO040 un ONKO060;<\/p>\n<p>Vesel\u012bbas pakalpojumu onkolo\u0123ijas jom\u0101 uzlabo\u0161anas pl\u0101ns 2025.\u20132027. gadam.<\/p>\n<p>Avots: LETA<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":13359,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"mic_cinema_image":0,"mic_focus":"","mic_cinema_focus":"","footnotes":"","_labiux_rail":0},"categories":[76,214],"tags":[1825],"mic_flag":[],"class_list":["post-22820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunakie-raksti","category-spec-vied","tag-plausu-vezis"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"603\" \/>\n\t\t<meta property=\"og:image:height\" content=\"434\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-17T08:21:44+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-17T08:21:44+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/#listItem\",\"name\":\"Jaun\\u0101kie raksti\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/#listItem\",\"position\":2,\"name\":\"Jaun\\u0101kie raksti\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#listItem\",\"name\":\"Plau\\u0161u v\\u0113zis &#8211; bie\\u017e\\u0101kais ar v\\u0113zi saist\\u012btais n\\u0101ves c\\u0113lonis Latvij\\u0101. Eksperti aicina ieviest valsts apmaks\\u0101tu skr\\u012bningu augsta riska grup\\u0101m\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#listItem\",\"position\":3,\"name\":\"Plau\\u0161u v\\u0113zis &#8211; bie\\u017e\\u0101kais ar v\\u0113zi saist\\u012btais n\\u0101ves c\\u0113lonis Latvij\\u0101. Eksperti aicina ieviest valsts apmaks\\u0101tu skr\\u012bningu augsta riska grup\\u0101m\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/#listItem\",\"name\":\"Jaun\\u0101kie raksti\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#newsarticle\",\"name\":\"Plau\\u0161u v\\u0113zis \\u2013 bie\\u017e\\u0101kais ar v\\u0113zi saist\\u012btais n\\u0101ves c\\u0113lonis Latvij\\u0101. Eksperti aicina ieviest valsts apmaks\\u0101tu skr\\u012bningu augsta riska grup\\u0101m - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"Plau\\u0161u v\\u0113zis &#8211; bie\\u017e\\u0101kais ar v\\u0113zi saist\\u012btais n\\u0101ves c\\u0113lonis Latvij\\u0101. Eksperti aicina ieviest valsts apmaks\\u0101tu skr\\u012bningu augsta riska grup\\u0101m\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/Cistiska-fibroze-plausas-slimiba-mazs.png\",\"width\":603,\"height\":434},\"datePublished\":\"2026-08-17T10:21:44+03:00\",\"dateModified\":\"2026-08-17T10:21:44+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#webpage\"},\"articleSection\":\"Jaun\\u0101kie raksti, Speci\\u0101lista viedoklis, plau\\u0161u v\\u0113zis\",\"dateline\":\"Published on August 17, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/\",\"name\":\"Plau\\u0161u v\\u0113zis \\u2013 bie\\u017e\\u0101kais ar v\\u0113zi saist\\u012btais n\\u0101ves c\\u0113lonis Latvij\\u0101. Eksperti aicina ieviest valsts apmaks\\u0101tu skr\\u012bningu augsta riska grup\\u0101m - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Saslimst\\u012bba ar plau\\u0161u v\\u0113zi pasaul\\u0113 un Eirop\\u0101 pieaug, \\u012bpa\\u0161i sievie\\u0161u vid\\u016b, turkl\\u0101t satrauco\\u0161s ir saslim\\u0161anas pieaugums to cilv\\u0113ku vid\\u016b, kuri nekad nav sm\\u0113\\u0137\\u0113ju\\u0161i. Vienlaikus sm\\u0113\\u0137\\u0113\\u0161ana joproj\\u0101m ir galvenais plau\\u0161u v\\u0113\\u017ea riska faktors un ar to ir saist\\u012bta absol\\u016bti liel\\u0101k\\u0101 da\\u013ca saslim\\u0161anas gad\\u012bjumu. Eksperti uzsver, ka l\\u012bdztekus sabiedr\\u012bbas izgl\\u012bto\\u0161anai par plau\\u0161u v\\u0113zi Latvij\\u0101 nepiecie\\u0161ams ieviest valsts\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/Cistiska-fibroze-plausas-slimiba-mazs.png\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#mainImage\",\"width\":603,\"height\":434},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\\\/#mainImage\"},\"datePublished\":\"2026-08-17T10:21:44+03:00\",\"dateModified\":\"2026-08-17T10:21:44+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs","description":"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts","canonical_url":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/#listItem","name":"Jaun\u0101kie raksti"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/#listItem","position":2,"name":"Jaun\u0101kie raksti","item":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#listItem","name":"Plau\u0161u v\u0113zis &#8211; bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#listItem","position":3,"name":"Plau\u0161u v\u0113zis &#8211; bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/#listItem","name":"Jaun\u0101kie raksti"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#newsarticle","name":"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs","headline":"Plau\u0161u v\u0113zis &#8211; bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png","width":603,"height":434},"datePublished":"2026-08-17T10:21:44+03:00","dateModified":"2026-08-17T10:21:44+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#webpage"},"articleSection":"Jaun\u0101kie raksti, Speci\u0101lista viedoklis, plau\u0161u v\u0113zis","dateline":"Published on August 17, 2026."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/","name":"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs","description":"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png","@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#mainImage","width":603,"height":434},"primaryImageOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/#mainImage"},"datePublished":"2026-08-17T10:21:44+03:00","dateModified":"2026-08-17T10:21:44+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs","og:description":"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts","og:url":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/","og:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png","og:image:secure_url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png","og:image:width":603,"og:image:height":434,"article:published_time":"2026-08-17T08:21:44+00:00","article:modified_time":"2026-08-17T08:21:44+00:00","twitter:card":"summary_large_image","twitter:title":"Plau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m - Medikamentu Inform\u0101cijas Centrs","twitter:description":"Saslimst\u012bba ar plau\u0161u v\u0113zi pasaul\u0113 un Eirop\u0101 pieaug, \u012bpa\u0161i sievie\u0161u vid\u016b, turkl\u0101t satrauco\u0161s ir saslim\u0161anas pieaugums to cilv\u0113ku vid\u016b, kuri nekad nav sm\u0113\u0137\u0113ju\u0161i. Vienlaikus sm\u0113\u0137\u0113\u0161ana joproj\u0101m ir galvenais plau\u0161u v\u0113\u017ea riska faktors un ar to ir saist\u012bta absol\u016bti liel\u0101k\u0101 da\u013ca saslim\u0161anas gad\u012bjumu. Eksperti uzsver, ka l\u012bdztekus sabiedr\u012bbas izgl\u012bto\u0161anai par plau\u0161u v\u0113zi Latvij\u0101 nepiecie\u0161ams ieviest valsts","twitter:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2022\/04\/Cistiska-fibroze-plausas-slimiba-mazs.png"},"aioseo_meta_data":{"post_id":"22820","title":null,"description":null,"keywords":null,"keyphrases":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-16 19:50:05","updated":"2026-10-16 19:50:05"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/\" title=\"Jaun\u0101kie raksti\">Jaun\u0101kie raksti<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tPlau\u0161u v\u0113zis \u2013 bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Jaun\u0101kie raksti","link":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/"},{"label":"Plau\u0161u v\u0113zis &#8211; bie\u017e\u0101kais ar v\u0113zi saist\u012btais n\u0101ves c\u0113lonis Latvij\u0101. Eksperti aicina ieviest valsts apmaks\u0101tu skr\u012bningu augsta riska grup\u0101m","link":"https:\/\/farmacija-mic.lv\/en\/plausu-vezis-biezakais-ar-vezi-saistitais-naves-celonis-latvija-eksperti-aicina-ieviest-valsts-apmaksatu-skriningu-augsta-riska-grupam\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=22820"}],"version-history":[{"count":0,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22820\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media\/13359"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=22820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=22820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=22820"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=22820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}